|
| 37922440 | Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community Collaboration. | JCO Oncol Pract | 2024 |
| 37916958 | Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations. | Cancer Discov | 2024 |
| 38060199 | First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results. | Clin Cancer Res | 2024 |
| 38092228 | Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial. | Ann Oncol | 2024 |
| 36865255 | Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and tumor microenvironment, overcoming multiple obstacles of CAR T therapy for solid tumors. | Res Sq | 2023 |
| 37714830 | Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment. | Nat Commun | 2023 |
| 37076495 | Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer. | NPJ Breast Cancer | 2023 |
| 37103597 | Feasibility of introducing a smartphone navigation application into the care of breast cancer patients (The FIONA Study). | Breast Cancer Res Treat | 2023 |
| 36643653 | Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer. | Ther Adv Med Oncol | 2023 |
| 36772966 | Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53. | Oncologist | 2023 |
| 34752147 | Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. | J Clin Oncol | 2022 |
| 35441995 | Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast). | Breast Cancer Res Treat | 2022 |
| 35671420 | Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study. | JCO Oncol Pract | 2022 |
| 35788722 | Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. | Nat Cancer | 2022 |
| 35852437 | Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network. | Oncologist | 2022 |
| 35592673 | An Initial Evaluation of Human Plasma cMLC-1: A Potential Protein Biomarker for Trastuzumab-Induced Cardiotoxicity, Breast Cancer Screening and Progression. | Front Oncol | 2022 |
| 35714678 | The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer. | J Natl Compr Canc Netw | 2022 |
| 35714673 | Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 36450763 | Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT). | NPJ Breast Cancer | 2022 |
| 35931884 | Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. | Nat Cancer | 2022 |
| 36051470 | Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer. | Ther Adv Med Oncol | 2022 |
| 34860318 | Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. | Breast Cancer Res Treat | 2022 |
| 34907082 | Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer. | Clin Cancer Res | 2022 |
| 35173164 | Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. | NPJ Breast Cancer | 2022 |
| 34990776 | Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. | Int J Radiat Oncol Biol Phys | 2022 |
| 33153384 | The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. | J Oncol Pharm Pract | 2021 |
| 33713742 | A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer. | Int J Radiat Oncol Biol Phys | 2021 |
| 33761455 | Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. | J Natl Compr Canc Netw | 2021 |
| 33504549 | Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. | Clin Cancer Res | 2021 |
| 34994617 | Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells. | JCO Precis Oncol | 2021 |
| 34794122 | NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. | J Natl Compr Canc Netw | 2021 |
| 34404686 | Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. | Cancer Discov | 2021 |
| 34417675 | Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. | Breast Cancer Res Treat | 2021 |
| 34077270 | Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. | J Clin Oncol | 2021 |
| 34302589 | A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. | Breast Cancer Res Treat | 2021 |
| 34349115 | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. | NPJ Breast Cancer | 2021 |
| 34120223 | Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). | Breast Cancer Res Treat | 2021 |
| 33978307 | Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. | Oncologist | 2021 |
| 34168046 | RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. | Clin Cancer Res | 2021 |
| 31492767 | Patient Preferences for Use of Archived Biospecimens from Oncology Trials When Adequacy of Informed Consent Is Unclear. | Oncologist | 2020 |
| 35050782 | Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. | JCO Precis Oncol | 2020 |
| 32101669 | Case 7-2020: A 52-Year-Old Man with a Mass in the Left Breast. | N Engl J Med | 2020 |
| 32046998 | Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. | Clin Cancer Res | 2020 |
| 32097092 | TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline <i>BRCA</i> Carriers With HER2-Negative Breast Cancer (the INFORM trial). | J Clin Oncol | 2020 |
| 31796517 | Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and <i>BRCA1/2</i> Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. | Clin Cancer Res | 2020 |
| 32610007 | Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic. | N Engl J Med | 2020 |
| 32712878 | A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry. | Breast Cancer Res Treat | 2020 |
| 32571788 | Identification of Somatically Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. | Clin Cancer Res | 2020 |
| 32700046 | Integration of Physician and Nursing Professional Efforts to Deliver Supportive Scalp Cooling Care to Oncology Patients at Risk for Alopecia. | Oncol Ther | 2020 |
| 32417409 | Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. | Int J Radiat Oncol Biol Phys | 2020 |